Jessica Zoe Bankey, MA,CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 12824 W 12th Ave, Airway Heights, WA 99001 Phone: 509-559-4600 Fax: 509-244-0906 |
Mashala Sauther Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 12824 W 12th Ave, Airway Heights, WA 99001 Phone: 509-481-1040 |
Melissa Mae Kehr Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 12824 W 12th Ave, Airway Heights, WA 99001 Phone: 509-559-4635 |
News Archive
A recent study on a sophisticated form of radiation treatment for breast cancer is inaccurate and has caused unnecessary concern among many patients, according to four top physician researchers.
Agfa HealthCare, a leading provider of diagnostic imaging and healthcare IT solutions, today announces that Western Maryland Regional Medical Center's recent upgrade to the newest version of IMPAX HeartStation ECG Management System has helped enable the rapid diagnosis and treatment of patients with posterior wall heart attacks. The Cumberland-based hospital is using the recently released features of IMPAX HeartStation to digitally review and archive 15-lead ECG studies.
Verbal abuse against nurses in the workplace, including abuse by other nurses, is both common and well-documented. The negative effects of that abuse and the adverse impact on patient care are also well-documented. Now, a study of newly licensed registered nurses (NLRNs) finds that nurses who are verbally abused by nursing colleagues report lower job satisfaction, unfavorable perceptions of their work environment, and greater intent to leave their current job.
The Paul G. Allen Family Foundation announced today the award of Allen Distinguished Investigator (ADI) grants to five teams of researchers with projects that will open new and innovative avenues of research in Alzheimer's disease by uncovering its elusive biological roots.
Curemark LLC, (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, announced that the company has begun enrolling patients in Phase III clinical trials for CM-AT, its autism treatment, at three additional clinical trial sites.
› Verified 2 days ago